Investigator Perspectives

Investigator Perspectives

Targeted Oncology presents Investigator Perspectives, a video series featuring key opinion leaders discussing how to approach and manage patients with different tumor types.

CAR T Therapy and Durable Responses in MCL

April 20th 2021

Frederick Locke, MD, discusses treatment options for patients with mantle cell lymphoma and the use of CAR T-cell therapy in clinics.

Examining the Role of Frontline BTKi Monotherapy in CLL

March 29th 2021

Expert perspectives on the use of frontline BTKi (Bruton's tyrosine kinase inhibitors) monotherapy in the treatment of chronic lymphocytic leukemia (CLL).

Belantamab Mafodotin in Clinical Practice for Heavily Pretreated MM

March 29th 2021

Sagar Lonial, MD, FACP, discusses the FDA’s recent accelerated approval of belantamab mafodotin for patients with triple-class refractory multiple myeloma (MM) and considers best practices for managing ocular toxicities.

Are Combinations the Answer in Metastatic RCC?

March 29th 2021

Robert J. Motzer, MD, provides perspective on recent data from the phase 3 CLEAR trial (Study 307)/KEYNOTE-581 for advanced renal cell carcinoma.

Continuing the Success Story With TRK Inhibitors

March 25th 2021

David S. Hong, MD, of the University of Texas MD Anderson Cancer Center, reacts to the growing interest around identifying NTRK gene fusions in various solid tumor types and treating appropriate patients with oral TRK inhibitors.

ASCO GI 2021 OS Update: IMbrave150

February 22nd 2021

Ruth He, MD, discusses the current treatment options for unresectable hepatocellular carcinoma.

Differentiated Thyroid Cancer with a Focus on Adverse Event Management

January 21st 2021

Steven Sherman, MD, FACE, provides insight on the treatment of radioactive iodine-refractory differentiated thyroid cancer and the management of adverse events.

ASH 2020 Updates: Improving Outcomes in TIE-NDMM

December 23rd 2020

Implications for assessing MRD status in patients with transplant-ineligible myeloma and treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone.

R/R Multiple Myeloma: Review of the CARTITUDE Trial

December 23rd 2020

Recent updates from the ASH 2020 annual meeting on the phase 1b/2 CARTITUDE-1 trial for relapsed/refractory multiple myeloma.

IMbrave150 for HCC

December 17th 2020

Data are reviewed from the phase 3 IMbrave150 trial for unresectable hepatocellular carcinoma.